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Editorialditorial 
The Namibian poliomyelitis outbreak 
and its consequences for South Africa 
This editorial is based on a Public Health Forum presented by the Centre for Infectious Diseases at the 
Faculty of Health Sciences, Stellenbosch University, on 22 June 2006. It summarises the most important 
facts about polio in the context of the 2006 outbreak of the disease in Namibia and aims to provide the 
practitioner with the necessary information to face the unexpected re-emergence in the sub-region of an 
almost forgotten disease.
Clinical aspects of polio 
Prof. Mark Cotton (Paediatric Infectious Diseases)
The “typical” clinical picture of poliomyelitis (commonly 
referred to as “polio”) is characterised by acute flaccid 
paralysis due to lower motor neuron damage. Patients 
suffer from weakness of the skeletal or cranial muscle 
groups and have an “anxious” facial expression. 
Superficial or deep reflexes disappear before the onset 
of paralysis, and there frequently is a symptom-free 
period, followed by the recurrence of symptoms and 
paralysis. The lower limbs are affected worse than 
the upper extremities. Autonomic instability, bladder 
paralysis and ileus can also occur.
Death may occur due to respiratory paralysis unless 
patients are put on artificial respirators (in the 1950s, 
the famous “iron lung” was used for such cases). The 
differential diagnosis includes Guillain-Barré syndrome 
(GBS), infection with neuropathogenic (non-polio) 
enteroviruses, rabies, botulism, and intoxications. Both 
congenital and neonatal polio may occur.
Some recovery of muscular function is common 
in survivors, but this may take six months or longer. 
In epidemics in developed countries in the early 
1950s, typically 5% of cases were fatal, 10% showed 
full recovery with no sequelae, while the remainder 
showed permanent paralysis to some degree. 
However, neurological involvement as the most severe 
manifestation of poliovirus infection occurs in only 
around 1% of those infected and is thus the exception 
rather than the rule. Much more commonly, poliovirus 
infection is asymptomatic or mild. The risk for paralytic 
disease increases with age (older patients also have 
a higher mortality rate), during pregnancy, following 
tonsillectomy (when bulbar polio disease occurs), recent 
DTP vaccination or trauma, and in those undertaking 
strenuous physical exercise. 
Abortive polio or “minor illness” includes fever 
(normally lower than in patients suffering from paralytic 
disease), malaise, anorexia and a sore throat. It 
normally lasts for about 72 hours. Some of these 
patients may progress to non-paralytic poliomyelitis or 
aseptic meningitis after a short interlude. They will suffer 
from fever, headache, neck stiffness, aching muscles, 
occasionally hyper- or paresthesia and symptoms such 
as anorexia, nausea, vomiting, diarrhoea or constipation. 
Recovery usually ensues after three to ten days.
The treatment is supportive; the only antiviral agent 
with anti-enterovirus activity is Pleconaril, which has 
been used in one child with vaccine-associated polio; 
however, this drug is currently not licensed.
Viruses, vaccines, and eradication 
Prof. Wolfgang Preiser (Virology)
Polio is the opposite of an emerging infectious disease: 
it is a very old disease of mankind and hopefully soon 
will be a thing of the past. The old Egyptians depicted 
individuals with the typical sequelae of paralytic polio. In 
1909, Landsteiner and Popper successfully transmitted 
the disease to nonhuman primates and, in 1949, 
Enders, Weller and Robbins first propagated poliovirus 
in vitro in cell culture.
There are three serotypes, polioviruses 1, 2 and 
3. They belong to the genus Enterovirus of the family 
Picornaviridae (derived from the Italian: pico = small, 
with a diameter of only 25 nm, and RNA for the viral 
nucleic acid). Polioviruses are non-enveloped and 
thus resistant to many commonly used detergents and 
disinfectants; at +4 ºC they remain infectious for weeks, 
and at room temperature will remain still for days.
Polioviruses enter the body via the oral route and 
replicate in the throat and gastrointestinal tract. The 
incubation period to the onset of paralysis is 10 to 
21 days. Large quantities of the virus are shed in the 
faeces for prolonged periods (typically several weeks). 
Transmission is faeco-orally, either directly from person 
to person (e.g. within households) or indirectly, e.g. via 
contaminated food or water, especially if hygiene and 
sanitation standards are poor.
Industrialised countries have seen improving hygiene 
during the 20th century, which, paradoxically, has made 
the polio problem worse by shifting the age at which the 
poliovirus infection is acquired from young childhood to 
higher age groups. With almost ubiquitous environmental 
contamination, nearly everyone was exposed within 
the first years of life, i.e. at an age when the chance 
of developing paralytic illness is comparatively small, 
followed by life-long immunity – an endemic situation. 
In contrast, higher age groups have a relatively higher 
risk of suffering severe manifestations should they 
become infected, which means that the numbers of 
paralytic cases increase despite an overall reduction in 
the number of infections. In addition, this infection often 
happened in waves, leading to an epidemic situation. 
In 1952, 21 000 cases of paralytic poliomyelitis were 
reported in the USA, and considerable efforts were 
undertaken to combat this dreaded disease.
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In 1954, Jonas Salk produced the first successful 
poliovirus vaccine. The Salk vaccine is trivalent (i.e. 
contains all three serotypes) and consists of formalin-
inactivated viruses. It is known as IPV (inactivated 
poliovirus vaccine). In 1961, a live attenuated poliovirus 
vaccine developed by Albert Sabin was licensed 
following extensive trials. It is known as OPV (oral 
poliovirus vaccine) and is normally used in its trivalent 
(tOPV) form, but more recently also for poliovirus type 1 
only (monovalent OPV = mOPV).
Both IPV and OPV have pros and cons. The oral 
(live attenuated) polio vaccine (OPV) is temperature 
sensitive, i.e. a reliable cold chain is required. However, 
it does not require injection. The vaccine viruses 
replicate in the vaccinee (meaning that comparatively 
smaller doses may be administered), and they induce 
mucosal immunity in the gut. OPV is almost 100% 
effective and, in addition, provides contact immunity: ~ 
25% of close contacts of vaccinees will be immunised 
inadvertently by becoming infected with the vaccine 
strains shed by vaccinees. A rare but significant side 
effect is vaccine-associated paralytic polio (VAPP). This 
complication occurs in one out of every two to three 
million doses OPV in susceptible individuals.
Inactivated (injectable) polio vaccine (IPV) is more 
stable, but requires injection. It does not reproduce 
in the vaccinee (therefore higher doses of antigen 
need to be given, and booster doses are required), 
but there is no risk of VAPP and it is unproblematic in 
immunocompromised and pregnant individuals. IPV 
does not induce mucosal immunity in the gut, it is not 
transmitted and therefore does not provide contact 
immunity.
The current vaccination schedule in South Africa 
includes OPV given routinely to all children at birth, 6 
weeks, 10 weeks, 14 weeks, 18 months and 5 years of 
age. Most importantly, polio vaccination works! Figure 
1 shows the relationship between global coverage with 
three doses of OPV between 1980 and 2004 and the 
annual reported incidence of polio disease.
The original plan was for the world to be certified polio-
free by 2000, but this first had to be delayed to 2005 and 
is now without a set date due to recent setbacks.
The following factors make it feasible to try to eradicate 
polio: 
•  it affects only humans, as there is no animal 
reservoir; 
•  an effective, safe and inexpensive vaccine is 
available; 
•  immunity following either immunisation or natural 
infection is reliable and long-lasting; 
•  there is no long-term carrier state (unfortunately this 
is not quite true, as we now know that individuals with 
agammaglobulinaemia do not clear the infection and 
may shed OPV strains for years or decades); and
•  poliovirus does not survive very long in the 
environment.
The polio eradication strategy is based on the following 
components:
1.  High routine infant immunisation coverage: at least 
three doses of OPV, plus a dose at birth in polio-
endemic countries, for at least 80% of children (South 
Africa has a coverage target of 90%).
2.  National immunisation days (NIDs): mass polio 
immunisation campaigns during which all children 
younger than five years are immunised, irrespective 
of their immunisation history, with two doses of OPV 
during two rounds; the aim is to rapidly interrupt 
possible chains of polio transmission.
3.  Acute flaccid paralysis (AFP) surveillance: the 
purpose of this is to detect possible cases of polio. 
This is achieved by targeting the “tip of the iceberg”, 
i.e. the small percentage of infected individuals who 
suffer from “classic” paralytic polio disease (see 
Figure 2). The target is notification of at least one 
case of AFP (due to GBS or other non-traumatic 
causes) per 100 000 children up to 15 years of age a 
year. At least 80% of these AFP cases must receive 
adequate laboratory investigations (by means of two 
stool samples obtained within two weeks of onset and 
tested for poliovirus). If these standards are fulfilled, 
AFP surveillance is functioning adequately and will 
be able to detect polio cases if they were to occur.
Figure 1: Global annual reported incidence of polio and 
coverage with three doses of OPV, 1980-2004 (Source: WHO 
vaccine-preventable diseases: monitoring system; 2005 global 
summary).
Figure 2:  “Classical” clinical cases of polio(myelitis), targeted 
by AFP surveillance, are just the “tip of the iceberg” 
“Typical” paralytic disease ~ 1 %
Non-specific symptoms ~ 5 10 %
Asymptomatic ~ 90 95 %
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The success of polio vaccination was so impressive 
that, in 1988, the World Health Assembly agreed to a 
worldwide eradication programme, making polio the 
second disease ever to be eradicated (after smallpox). 
4.  Mop-up immunisation campaigns to interrupt final 
chains of transmission: house-to-house vaccination 
of all children younger than five years of age within 
a high-risk geographic area or population with 
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two doses of OPV, again regardless of previous 
immunisation history.
The last laboratory-confirmed case of polio in South 
Africa occurred in KwaZulu-Natal in 1989. AFP was 
made notifiable in 1994, and several national polio 
immunisation campaigns have been conducted (in 
1995, 1996, 1997 and 2000; in the Western Cape 
in 2002). South Africa is currently working on the 
containment of laboratory stocks of wild poliovirus.
The global effort and Rotary’s role 
Dr Peter Vurgarellis (Rotary)
Rotary is a worldwide organisation of business and 
professional leaders that provides humanitarian 
service, encourages high ethical standards in all 
vocations, and helps build goodwill and peace in the 
world. Approximately 1.2 million Rotarians belong to 
more than 32 000 clubs in more than 200 countries and 
geographical areas.
Rotary’s involvement in polio eradication began 
in 1979, after a talk by Dr Sabin, with a five-year 
commitment to provide and help deliver polio vaccine 
to six million children in the Philippines. It was the first 
project of the new Health, Hunger and Humanity (3-H) 
programme. In the next four years, similar five-year 
commitments were approved for Haiti, Bolivia, Morocco, 
Sierra Leone and Cambodia.
In the early 1980s, Rotary began planning for the 
most ambitious programme in its history – to immunise 
all of the world’s children against polio. The plan 
required collaboration with international, national and 
local health agencies. Dr Canseco invited Dr Albert 
Sabin, the developer of the oral polio vaccine, to serve 
as a special consultant to the committee.
Rotary’s pledge of US$120 million to fund its 
PolioPlus programme was announced in October 1985 
at the 40th anniversary of the United Nations (UN). This 
ambitious commitment electrified the global public 
health community. Within three years, Rotarians had 
more than doubled their fundraising goal, donating 
US$247 million. By the time the world is certified polio 
free, Rotary’s contribution to the global polio eradication 
effort will exceed US$600 million.
PolioPlus funds have funded transportation and other 
operational costs associated with vaccine delivery, 
surveillance efforts (including laboratory needs) to 
identify areas where the virus circulates, and training 
for healthcare workers and volunteers involved in the 
immunisation process.
Rotarians have delivered vaccine by camels, 
helicopters, trucks and motorbikes, staffed immunisation 
posts, raised community awareness of the value of 
immunisation and, in the process, have helped to 
mobilise 10 million volunteers.
The Global Polio Eradication Initiative is recognised 
worldwide as a model of public and private cooperation 
in pursuit of a humanitarian goal. In the words of UN 
General Secretary Kofi Annan, “Rotary’s PolioPlus 
programme is a shining example of the achievements 
made possible by cooperation between the UN and 
non-governmental organisations”.
The Namibian polio outbreak: re-
introduction into fertile soil 
Dr Gert van Zyl (Virology)
As of 28 June 2006, at least 17 people have died and 
136 have presented with paralysis in a polio outbreak in 
Namibia that started in May 2006. Before the outbreak, 
Namibia had been polio free since 1995. So how did this 
happen?
The widely used emerging infectious disease news 
list, Promed, reported on 2 June 2006 that “panic is 
sweeping through suburbs north of Katutura” (i.e. near 
the capital Windhoek) after three people had died and 
19 others were hospitalised with a disease that then still 
had to be identified. At that stage it was unclear what 
the aetiology of this paralytic disease was; the age of 
those affected in fact made polio an unlikely candidate, 
at least according to “experts”.
The index case – which is not necessarily the “first” 
case in the outbreak but somebody with access to 
private health care and thus state-of-the-art laboratory 
diagnosis – was a 39-year-old man from Aranos, 450 km 
by road from Windhoek. He was admitted to a private 
hospital in Windhoek on 25 April and underwent a 
cholecystectomy on 27 April. He was then discharged 
and initially recovered well.
However, he then fell ill again with rigors and fever, 
stomach pain and tenderness and, on 8 May, had 
an onset of weakness in his legs and dyspnoea. He 
was subsequently referred to Windhoek, where he 
was intubated and ventilated. A stool specimen was 
collected on 15 May. A type 1 poliovirus was isolated 
from the specimen and determined to be wild-type virus 
by the National Institute for Communicable Diseases 
(NICD) in Johannesburg. 
Namibia is a vast country with only about two million 
inhabitants. Its Gini coefficient (a measure of income 
disparity) is one of the highest in the world, at 70.7 on a 
scale up to 100, with 0 representing perfect equality. Its 
performance with respect to routine polio immunisation 
coverage and AFP surveillance meets WHO targets: 
coverage with three doses of OPV is around 80%, and 
AFP notifications stand at 2/100 000, with an adequate 
stool collection rate of 88%.
The country nevertheless provided fertile soil for the 
current outbreak. Katutura means “a place to stay” or “we 
have no per-manent habitation” in the Herero language 
and is a partially informal settlement in which 60% of 
Windhoek’s 200 000 inhabitants live. Of these, 30% did 
not have adequate sanitation in 2001. Katutura also 
serves as a reception area for immigrants from rural 
Namibia and neighbouring countries such as Angola.
A genetic analysis of the index case’s virus by the 
NICD showed that the Namibian isolate was closely 
related to type 1 polioviruses isolated in Benguela 
province in Angola in May and June 2005 and which 
belonged to a South Asian genotype that originated in 
India. Angola has only 42% OPV coverage. The last 
polio case there was notified in November 2005.
One is left to wonder what happened between then 
and May 2006, when this virus re-emerged in Namibia. 
Had there perhaps been a “silent epidemic”, with 
AFP cases being missed either in Angola or Namibia, 
despite seemingly adequate vaccination rates?
Unusual features of the ongoing Namibian outbreak 
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are the age groups affected. The initial 34 AFP cases 
had ages ranging from 5 to 76 years; 13 of the 18 cases 
with age indicated (72%) are people between the ages 
of 20 and 35 years. This is highly unusual for polio. The 
death rate of 15 out of 96 cases is also unusually high.
Possible explanations could be that the adults were 
not immunised and, due to a lack of natural exposure in 
sparsely populated Namibia prior to the vaccination era, 
had not been infected with wild polioviruses. Primary or 
secondary vaccine failure might also play a role. A 
higher age at infection means a higher attack rate for 
AFP and increased severity, which could explain the 
observed high mortality, although the mode of exposure 
and size of the inoculum may also have contributed to 
this.
By the time polio was established as the aetiology 
behind the cases of paralysis, seven deaths had 
already occurred and more than twenty AFP cases 
had been reported. It can only be speculated how the 
silent infections would have occurred (see Figure 2). In 
response, the entire Namibian population was targeted 
in a NID using monovalent OPV-1 on 21 June 2006; two 
more NIDs are planned.
The most important lesson to be learnt from this crisis 
is that each and every case of AFP is important and 
must be diagnosed appropriately. It also shows that 
political and socio-economic factors remain important.
The South African response to the 
polio outbreak in Namibia 
Dr Neil Cameron (Public Health)
To prepare South Africa for the possible importation 
of polio from neighbouring Namibia, awareness 
amongst healthcare staff has been heightened through 
circulars, etc. to ensure the immediate reporting of 
suspected cases to allow for prompt investigation and 
an appropriate and timely response. The importance of 
personal hygiene has been stressed and advice has 
been issued for travellers to Namibia. Immunisation 
for travellers is being provided at primary care clinics. 
Because the Namibian outbreak seems to largely 
affect adults rather than children, AFP surveillance has 
been extended to all age groups (instead of only those 
younger than 15). 
The definition of suspected polio is any case of AFP 
characterised by sudden loss of strength, tone and/or 
reflexes in a limb or limbs in a child aged younger than 
15 years, for which no other presenting cause such as 
trauma is evident at onset. Such cases of AFP must be 
reported even if they do not “look like polio”, even if the 
child is fully vaccinated, and even if the onset occurred 
up to 60 days previously. A case investigation form must 
be completed, recording accurate address information 
to facilitate tracing and follow-up. Two stool specimens 
are collected 24 hours apart and shipped frozen to the 
designated laboratory at NICD in Johannesburg. The 
infection control staff at provincial and private hospitals 
or staff at the nearest Public Health Laboratory Service 
should be able to provide details of specimen collection 
and shipment.
In addition to increased monitoring and strengthening 
of routine immunisation coverage, the national mass 
immunisation campaign originally planned for July 2007 
is being brought forward to September 2006.
Recommendations for travellers 
Dr Jantjie Taljaard (Adult Infectious Diseases)
Not very much is known about the current outbreak 
in Namibia as regards its epidemiology, geographic 
spread, etc. However, the potential severity of the 
disease, which may lead to irreversible paralysis and 
even death, is well documented. In comparison, the 
risk associated with the only specific intervention, 
immunisation, is insignificant. 
The Epidemiology Unit of the NICD issued a 
recommendation on 15 June 2006 that all travellers 
to Namibia (including returning residents) are advised 
to obtain a booster dose of polio vaccine at least 10 
to 14 days before travelling. Should travel commence 
sooner than 10 to 14 days, the individuals should still 
be immunised (the idea behind this probably being 
that although specific immunity will not develop soon 
enough, the “ecological niche” in the gastrointestinal 
tract will be occupied by OPV strains and thus will not 
be available for wild poliovirus).
Trivalent OPV is the vaccine best suited for 
eradicating polio as it provides herd immunity, is 
cheap, easily accessed and recommended by 
the WHO. It is currently provided free of charge at 
government clinics. It is safe, with a very low rate 
of vaccine-associated polio paralysis (VAPP). The 
only absolute contraindication to vaccination with 
OPV is severe humeral immunodeficiency. For these 
individuals, IPV alone is available as a Section 21 
drug through the Medicines Control Council (MCC) 
or using the combination tetanus, diphtheria and IPV 
(TdP) vaccine. IPV is also recommended for pregnant 
women undertaking essential travel to Namibia. In 
addition, one should also consider giving IPV to those 
with severe immunosuppression and to adults who 
have never before been immunised against polio.
As polio is transmitted via the faecal-oral route, it is 
extremely important that high levels of general hygiene 
be maintained at all times. This includes frequent hand 
washing and the consumption of clean (preferably 
bottled) water and non-contaminated food.
No vaccination is recommended for people entering 
South Africa from Namibia. These people should be 
advised to report to the nearest healthcare facility if 
they develop acute onset of paralysis and to inform the 
healthcare worker of their visit to Namibia. 
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